NeoGenomics (NEO) Receives Daily Coverage Optimism Score of 0.18

Press coverage about NeoGenomics (NASDAQ:NEO) has trended somewhat positive on Friday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. NeoGenomics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.3665358952027 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of NeoGenomics (NASDAQ NEO) opened at $8.51 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.99. The company has a market capitalization of $689.31, a PE ratio of -24.31, a PEG ratio of 3.52 and a beta of 0.84. NeoGenomics has a 12 month low of $7.12 and a 12 month high of $11.63.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. The company had revenue of $63.05 million during the quarter, compared to the consensus estimate of $63.11 million. NeoGenomics had a negative return on equity of 18.37% and a negative net margin of 8.09%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the business posted $0.04 EPS. analysts anticipate that NeoGenomics will post 0.04 earnings per share for the current year.

Several research firms have recently weighed in on NEO. CIBC set a $19.00 price objective on NeoGenomics and gave the stock a “neutral” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 23rd. Scotiabank set a $22.00 target price on NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Finally, Royal Bank of Canada set a $23.00 target price on NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. NeoGenomics presently has an average rating of “Buy” and a consensus target price of $15.83.

ILLEGAL ACTIVITY WARNING: “NeoGenomics (NEO) Receives Daily Coverage Optimism Score of 0.18” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply